Literature DB >> 27661969

Gastrointestinal Polyposis in Cowden Syndrome.

Ruthy Shaco-Levy1, Kory W Jasperson, Katie Martin, N J Samadder, Randall W Burt, Jian Ying, Mary P Bronner.   

Abstract

GOALS: To further characterize the gastrointestinal manifestations of Cowden syndrome in clinically well-annotated patients to improve the diagnosis of this syndrome.
BACKGROUND: The gastrointestinal manifestations of Cowden Syndrome, an important heritable and multiorgan cancer syndrome, are not well defined. Proper diagnosis is essential for effective cancer surveillance and prevention in these patients. STUDY: Cowden patients with gastrointestinal polyps were selected for medical record and pathologic slide review.
RESULTS: Of 19 total patients, genetic testing revealed pathogenic PTEN mutations in 12. Pan-colonic (11-patients, 58%) and pan-gastrointestinal (8-patients, 42%) polyp distributions were common. Inflammatory (juvenile) polyps were the most common of the hamartomatous polyp (18 patients, 95%), along with expansive lymphoid follicle polyps (12 patients, 63%), ganglioneuromatous polyps (10 patients, 53%), and intramucosal lipomas (5 patients, 26%). The findings of 2 or more hamartomatous polyp types per patient emerged as a newly described and highly prevalent (79%) feature of Cowden syndrome. Ganglioneuromatous polyps, rare in the general population, and intramucosal lipomas, which may be unique to Cowden syndrome, should both prompt further evaluation. Colonic adenomas and adenocarcinomas were common; 10 patients (53%) had single and 3 (16%) had ≥3 adenomas, whereas 2 (11%) had colonic adenocarcinoma, strengthening the emerging association of colorectal cancer with Cowden syndrome.
CONCLUSIONS: The clinical phenotypes and gastrointestinal manifestations in Cowden syndrome are quite variable but this series adds the following new considerations for this syndromic diagnosis: multiple gastrointestinal hamartomas, especially 2 or more hamartoma types, and any intramucosal lipomas or ganglioneuromas. These features should warrant consideration of Cowden syndrome.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27661969     DOI: 10.1097/MCG.0000000000000703

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  7 in total

Review 1.  [Hereditary colorectal cancer : An update on genetics and entities in terms of differential diagnosis].

Authors:  T T Rau; H Dawson; A Hartmann; J Rüschoff
Journal:  Pathologe       Date:  2017-05       Impact factor: 1.011

2.  Clinicopathologic analysis and subclassification of benign lipomatous lesions of the colon.

Authors:  Samuel L Barron; Raul S Gonzalez
Journal:  Virchows Arch       Date:  2018-11-19       Impact factor: 4.064

3.  Intramucosal lipomas of the colon implicate Cowden syndrome.

Authors:  Aybuke Caliskan; Wendy K Kohlmann; Kajsa E Affolter; Erinn Downs-Kelly; Priyanka Kanth; Mary P Bronner
Journal:  Mod Pathol       Date:  2017-12-01       Impact factor: 7.842

4.  Fibroblastic Polyps: A Novel Polyp Subtype in Cowden Syndrome.

Authors:  Bradley Anderson; Thomas Smyrk; Seth Sweester
Journal:  ACG Case Rep J       Date:  2017-10-11

Review 5.  PTEN Hamartoma Tumor Syndrome and Immune Dysregulation.

Authors:  Marc Eissing; Lise Ripken; Gerty Schreibelt; Harm Westdorp; Marjolijn Ligtenberg; Romana Netea-Maier; Mihai G Netea; I Jolanda M de Vries; Nicoline Hoogerbrugge
Journal:  Transl Oncol       Date:  2018-11-30       Impact factor: 4.243

Review 6.  The Gut-Brain-Microbiome Axis and Its Link to Autism: Emerging Insights and the Potential of Zebrafish Models.

Authors:  David M James; Elizabeth A Davidson; Julio Yanes; Baharak Moshiree; Julia E Dallman
Journal:  Front Cell Dev Biol       Date:  2021-04-15

7.  Detection and Yield of Colorectal Cancer Surveillance in Adults with PTEN Hamartoma Tumour Syndrome.

Authors:  Meggie M C M Drissen; Janet R Vos; Dorien T J van der Biessen-van Beek; Rachel S van der Post; Iris D Nagtegaal; Mariëtte C A van Kouwen; Tanya M Bisseling; Nicoline Hoogerbrugge
Journal:  Cancers (Basel)       Date:  2022-08-19       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.